Inhaled muco-trapping antibody therapy for RSV (IN-002)
Pharmacokinetics analysis from first-in-human study of IN-002, a potent inhaled muco-trapping antibody therapy for RSV
['FUNDING_SBIR_2'] · INHALON BIOPHARMA, INC. · NIH-11123509
This project tests an inhaled antibody called IN-002 that aims to trap and clear RSV from the airways to help infants, children, and adults at risk of severe RSV.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | INHALON BIOPHARMA, INC. (nih funded) |
| Locations | 1 site (Morrisville, UNITED STATES) |
| Trial ID | NIH-11123509 on ClinicalTrials.gov |
What this research studies
If I join, I would inhale IN-002 using a handheld device so the antibody goes straight to my airways where RSV lives. The team will measure how long the antibody stays in airway mucus and blood and monitor safety and side effects. IN-002 is designed to stick to the RSV F protein and trap virus particles in mucus so natural clearance can remove them. Early work will focus on first-in-human pharmacokinetics and safety, building toward use in people most affected by RSV.
Who could benefit from this research
Good fit: Ideal candidates would be adults or older children who meet the study's eligibility criteria and are either infected with RSV or at increased risk for severe RSV.
Not a fit: People without airway RSV infection, those already critically ill in the hospital, or those with known allergies to antibody products may not receive benefit from this early-phase work.
Why it matters
Potential benefit: If successful, this could shorten or prevent RSV lung infections by clearing the virus more quickly from the airways.
How similar studies have performed: Systemic monoclonal antibodies have helped prevent severe RSV, but inhaled muco-trapping antibodies are a newer approach with promising lab and animal results and limited human data so far.
Where this research is happening
Morrisville, UNITED STATES
- INHALON BIOPHARMA, INC. — Morrisville, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SCOTT, DAVID W — INHALON BIOPHARMA, INC.
- Study coordinator: SCOTT, DAVID W
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.